Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.

doi:10.18632/oncotarget.1883

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.

Oncotarget - 15 May 2014

Cazes Alex, Lopez-Delisle Lucille, Tsarovina Konstantina, Pierre-Eugène Cécile, De Preter Katleen, Peuchmaur Michel, Nicolas André, Provost Claire, Louis-Brennetot Caroline, Daveau Romain, Kumps Candy, Cascone Ilaria, Schleiermacher Gudrun, Prignon Aurélie, Speleman Frank, Rohrer Hermann, Delattre Olivier, Janoueix-Lerosey Isabelle

Abstract excerpt

Activating mutations of the ALK (Anaplastic lymphoma Kinase) gene have been identified in sporadic and familial cases of neuroblastoma, a cancer of early childhood arising from the sympathetic nervous system (SNS). To decipher ALK function in neuroblastoma predisposition and oncogenesis, we have characterized knock-in (KI) mice bearing the two most frequent mutations observed in neuroblastoma patients. A dramatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Integrases

Share to N-Myc Proto-Oncogene Protein

Share to Neuroblastoma

Share to Neurogenesis

Share to Proto-Oncogene Proteins c-ret

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 24811913
DOI: 10.18632/oncotarget.1883
PMCID: PMC4058037

Genes

ALK
MYCN
RET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.PMID 24811913Read ↗

The ALK receptor in sympathetic neuron development and neuroblastoma.Semantic proximity Read ↗

Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic MiceSemantic proximity Read ↗

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted TreatmentSemantic proximity Read ↗

ALK R1275Q mutation drives expansion of SCP-like cells during sympathoadrenal commitment and primes neuroblastoma initiationSemantic proximity Read ↗

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived CancerSemantic proximity Read ↗

Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition.Semantic proximity Read ↗

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.Semantic proximity Read ↗

Neuroblastoma models for insights into tumorigenesis and new therapies.Semantic proximity Read ↗

Neuroblastoma and Its Zebrafish Model.Semantic proximity Read ↗

Activating mutations in ALK provide a therapeutic target in neuroblastoma.Semantic proximity Read ↗

ALK in Neuroblastoma: Biological and Therapeutic ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.